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Objective: To determine use of class and type of cardioprotective pharmacological agents in
patients with stable coronary heart disease (CHD) we performed a prescription audit.
Methods: A cross sectional survey was conducted in major districts of Rajasthan in years
2008e09. We evaluated prescription for classes (anti-platelets, b-blockers, angiotensin
converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), calcium channel
blockers (CCB) and statins) and specific pharmacological agents at clinics of physicians in
tertiary (n ¼ 18), secondary (n ¼ 69) and primary care (n ¼ 43). Descriptive statistics are
reported.
Results: Prescriptions of 2290 stable CHD patients were audited. Anti-platelet use was in
2031 (88.7%), b-blockers 1494 (65.2%), ACE inhibitors 1196 (52.2%), ARBs 712 (31.1%), ACE
inhibitors e ARB combinations 19 (0.8%), either ACE inhibitors or ARBs 1908 (83.3%), CCBs
1023 (44.7%), statins 1457 (63.6%) and other lipid lowering agents in 170 (7.4%). Among anti-
platelets aspirineclopidogrel combination was used in 88.5%. Top three molecules in b-
blockers were atenolol (37.8%), metoprolol (26.4%) and carvedilol (11.9%); ACE inhibitors
ramipril (42.1%), lisinopril (20.3%) and perindopril (10.9%); ARB’s losartan (47.7%), valsartan
(22.3%) and telmisartan (14.9%); CCBs amlodipine (46.7%), diltiazem (29.1%) and verapamil
(9.5%) and statins were atorvastatin (49.8%), simvastatin (28.9%) and rosuvastatin (18.3%).
Use of metoprolol, ramipril, valsartan, diltiazem and atorvastatin was more at tertiary care,
and atenolol, lisinopril, losartan, amlodipine and simvasatin in primary care (p < 0.01).
Conclusions: There is low use of b-blockers, ACE inhibitors, ARBs and statins in stable CHD
patients among physicians in Rajasthan. Significant differences in use of specific molecules
at primary, secondary and tertiary healthcare are observed.
Copyright ª 2013, Cardiological Society of India. All rights reserved.; fax: þ91 1414008151.
l.com (K.K. Sharma).
2013, Cardiological Society of India. All rights reserved.
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 2 5 0e2 5 5 2511. Introduction nondihydropyridine calcium channel blockers (CCBs), potas-Table 1 e Cardiovascular pharmacological agents
prescribed in stable CHD patients.
Pharmacological
molecules
Patient
numbers
Proportion within
each drug class %
Anti-platelet agents (n ¼ 2031)
Aspirin alone 234 11.5
Aspirineclopidogrel 1797 88.4
b-Blockers (n ¼ 1494)
Atenolol 566 37.8
Metoprolol 394 26.4
Carvedilol 178 11.9
Bisoprolol 139 9.3
Nebivolol 108 7.2
Propanolol 74 4.9
Others 35 2.3
Angiotensin converting enzyme inhibitors (n ¼ 1196)
Ramipril 504 42.1
Lisinopril 243 20.3
Perindopril 131 10.9
Enalapril 147 12.3Patients with coronary heart disease (CHD) are at higher risk
for subsequent cardiac events and mortality. A number of
drugs have been shown to reduce second cardiovascular
events and mortality in large randomized controlled trials.1
These are anti-platelets, b-blockers, angiotensin converting
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs)
and cholesterol lowering statins.2 Current guidelines for the
prevention of cardiovascular events among individuals with
established CHD recommend anti-platelets, b-blockers, ACE
inhibitors and statins in all individuals.3,4 However, there is
substantial gap between recommendations and imple-
mentation of these medicines in routine clinical practice.5
Recent studies have also shown that second and third
generation pharmacological agents among these car-
dioprotective drug classes have important pharmacological
and clinical benefits. For example, metoprolol has been re-
ported to be better than atenolol in reduction of cardiovas-
cular events,6 ramipril and perindopril are more
cardiovascular protective as compared to first generation ACE
inhibitors,7,8 newer ARBs such as telmisartan are equivalent
to ACE inhibitors in cardioprotective effects,9 and newer sta-
tins such as atorvastatin and rosuvastatin have dosing ease
and less toxicity over older statins.10,11 Studies in developed
countries have reported that there occurs a substantial
change in pharmacological drug use over time and also newer
molecules are rapidly absorbed into practice once the clinical
trial evidence emerges.12 Use of different pharmacological
agents and, specifically, newer molecules has not been stud-
ied in patients with CHD in India. To evaluate the use of
various cardioprotective medicines and to document the use
of different pharmacological agents within the broad class of
drugs, used for secondary prevention in CHD patients, we
performed a cross sectional study.
Captopril 87 7.3
Trandolapril 54 4.5
Others 30 2.5
Angiotensin receptor blockers (n ¼ 712)
Losartan 340 47.7
Valsartan 159 22.3
Telmisartan 106 14.9
Candesartan 70 9.8
Others 37 5.2
Calcium channel blockers (n ¼ 1023)
Amlodipine 485 47.5
Diltiazem 298 29.1
Verapamil 97 9.5
Nifedipine 46 4.5
Felodipine 47 4.6
Nicardipine 23 2.2
Others 27 2.6
Statins (n ¼ 1457)
Atorvastatin 726 49.8
Simvastatin 422 28.9
Rosuvastatin 267 18.3
Others 42 2.8
Other lipid lowering (n ¼ 170)
Fibrates 71 41.7
Niacin 29 17.0
Orlistat 35 20.6
Others 35 20.62. Methods
The study was approved by the institutional ethics commit-
tee. Details of the study protocol and methods have been re-
ported earlier.13 In brief, a proforma was prepared that
included demographic details of patients, diagnoses, and drug
prescriptions. Data on demographic and personal detail of
physicians were also collected. Physicians were classified as
primary care physicians who had basic qualifications and
were working in rural or urban clinics and dispensaries; sec-
ondary level physicians who were having a postgraduate
qualification in internal medicine and practising indepen-
dently or in government clinics, primary health centers or
secondary level government or private hospitals; and tertiary
level physicians were those with subspecialty qualification in
cardiology or cardiac surgery and working at tertiary level
hospitals with cardiac invasive and surgical management.
The trade names of drugs were deciphered and classified into
pharmacological groups that included aspirin, clopidogrel or
other anti-platelets agents, b-blockers, ACE inhibitors or ARBs,
statins, other lipid lowering medicines such as fenofibrate,
short- and long-acting nitrates, dihydropyridine orsium channel openers (eg, nicorandil), metabolic modulators
(eg, trimetazidine), antioxidants, multivitamins, diabetic
medications, and other medications.
The study was performed at all large districts of Rajasthan
state over a period of 15 months from September 2007 to
December 2008. Consent from the physicians prescribing at
primary, secondary, and tertiary sites was obtained and the
prescriptions were studied during a single day at the local
pharmacy. This was to minimize bias and negate the influ-
ence of changing the prescribing habit once awareness of
monitoring was apparent. We could evaluate prescriptions of
43 general practitioners or primary care physicians, 61
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 2 5 0e2 5 5252internists and 8 diabetologists or secondary care physicians,
and 18 cardiologists in tertiary care. Interviews were orga-
nized with the patients after their consent and only those
patients who had an established diagnosis of CHD were
included. Approximately, 60% of eligible patients (3013/5000)
recruited from the outpatient clinics of primary, secondary,
and tertiary healthcare facilities or tertiary care hospitals
agreed to provide details of prescriptions. Twenty pre-
scriptions were illegible and 2993 were included in the initial
prescription audit.13 In the present study, we excluded pre-
scriptions from patients recently discharged from tertiary
care hospitals and therefore results of 2290 prescriptions are
presented. The medicines obtained from these prescriptions
were deciphered and trade names translated into pharmaco-
logical molecules.Table 2 e Cardiovascular drug use at primary, secondary, and
Molecules used Primary
care (297)
Sec
care
Anti-platelets (n ¼ 2031)
Aspirin 48 (24.7) 16
Aspirineclopidogrel 146 (75.2) 119
b-Blockers (n ¼ 1494)
Atenolol 84 (41.2) 36
Metoprolol 27 (13.2) 24
Carvedilol 17 (8.3) 12
Bisoprolol 23 (11.3) 8
Nebivolol 8 (3.9) 5
Propanolol 23 (11.3) 4
Others 22 (10.8) 1
Angiotensin converting enzyme inhibitors (n ¼ 1196)
Ramipril 34 (24.8) 28
Lisnopril 36 (26.3) 17
Perindopril 3 (2.2) 7
Enalapril 33 (24.1) 9
Captopril 23 (16.8) 6
Trandolapril 4 (2.9) 3
Others 4 (2.9) 2
Angiotensin receptors blockers (n ¼ 712)
Losartan 40 (54.7) 24
Valsartan 9 (12.3) 11
Telmisartan 8 (10.9) 6
Candesartan 14 (19.1) 5
Others 2 (2.7) 2
Calcium channel blockers (n ¼ 1023)
Amlodipine 106 (61.6) 32
Diltiazem 27 (15.7) 20
Verapamil 8 (4.6) 6
Nifedipine 11 (6.4) 3
Felodipine 12 (6.9) 3
Nicardipine 2 (1.1)
Others 6 (3.5) 2
Statins (n ¼ 1457)
Atorvastatin 27 (40.9) 47
Simvastatin 35 (53.0) 28
Rosuvastatin 3 (5.3) 15
Others 1 (1.7) 2
Other lipid lowering drugs (n ¼ 170)
Fibrates 2 (66.7) 4
Niacin 0 (0.0) 2
Orlistat 0 (0.0) 3
Others 1 (33.3) 12.1. Statistical analyses
All the data were computerized and SPSS statistical package
used for analyses. Descriptive statistics are reported. Signifi-
cance of difference in drug use at primary, secondary and
tertiary care was evaluated by c2 test.3. Results
A total of 2290 prescriptions obtained at different levels of care
(297 primary, 1484 secondary and 509 tertiary) were audited.
The mean age of patients was 60.9  8 years and median
duration of disease was 2 years. Majority of patients were
male (67.3%) and from urban (86.1%) locations. Anti-platelettertiary healthcare.
ondary
(1484)
Tertiary
care (509)
X2 ( p-value)
2 (11.9) 24 (5.0) 0.0001
2 (88.0) 459 (95.0) 0.0001
6 (39.3) 116 (32.2) 0.21
9 (26.8) 118 (32.7) 0.0001
0 (12.9) 41 (11.4) 0.36
9 (9.5) 27 (7.5) 0.36
3 (5.7) 47 (13.0) 0.0001
3 (4.6) 8 (2.2) 0.0001
0 (1.1) 3 (0.8) 0.0001
9 (38.2) 181 (59.9) 0.0001
0 (22.5) 34 (11.2) 0.0006
9 (10.4) 51 (16.9) 0.0001
8 (12.9) 16 (5.3) 0.0001
1 (8.1) 3 (0.9) 0.0001
8 (5.0) 12 (4.0) 0.0001
1 (2.8) 5 (1.6) 0.54
9 (48.6) 51 (40.1) 0.0008
7 (22.8) 33 (26.0) 0.009
9 (13.5) 29 (22.8) 0.14
0 (9.7) 6 (4.7) 0.009
7 (5.3) 8 (6.3) 0.35
1 (46.5) 56 (35.0) 0.0001
6 (29.9) 65 (40.6) 0.08
7 (9.7) 22 (13.7) 0.36
3 (4.8) 2 (1.2) 0.003
3 (4.8) 2 (1.2) 0.001
9 (1.3) 12 (7.5) 0.002
0 (2.9) 1 (0.6) 0.04
8 (50.7) 221 (52.3) 0.0001
3 (30.0) 104 (24.6) 0.0053
7 (16.6) 76 (18.0) 0.0001
5 (2.6) 21 (5.0) 0.0003
7 (42.3) 22 (39.3) 0.01
4 (21.6) 5 (8.9) 0.06
0 (27.0) 5 (8.9) 0.01
0 (9.0) 24 (42.8) 0.0001
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hibitors in 1196 (52.2%), ARBs in 712 (31.1%), ACE inhibitors e
ARB combinations in 19 (0.8%), either ACE inhibitors or ARBs
in 1908 (83.3%), CCBs in 1023 (44.7%), statins in 1457 (63.6%)
and other lipid lowering agents in 170 (7.4%) (Table 1). In the
anti-platelet class of drugs, 11.5% patientswere on aspirin and
88.5% were on aspirineclopidogrel combination. Top three
molecules prescribed among b-blockers were atenolol (37.8%),
metoprolol (26.4%) and carvedilol (11.9%); among ACE in-
hibitors were ramipril (42.1%), lisinopril (20.3%) and peri-
ndopril (10.9%); among ARBs were losartan (47.7%), valsartan
(22.3%) and telmisartan (14.9%); among CCBs were amlodipine
(46.7%), diltiazem (29.1%) and verapamil (9.5%); and among
statins were atorvastatin (49.8%), simvastatin (28.9%) and
rousvastatin (18.3%). Details of use of other pharmacological
entities are shown in Table 1.
Use of various cardiovascular pharmacological drugs at
different levels of care is shown in Table 2. At primary, sec-
ondary and tertiary care levels, respectively, the use of leading
molecules was aspirineclopidogrel in 75.2, 88.0 and 95.0%;
atenolol in 41.2, 39.3 and 32.2%; metoprolol in 13.2, 26.8 and
32.7%; ramipril in 24.8, 38.2 and 59.9%; lisinopril in 26.3, 22.5
and 11.2%; losartan in 54.7, 48.6 and 40.1%; valsartan in 12.3,
22.8, 26.0%; amlodipine in 61.6, 46.5 and 35.0%; diltiazem in
15.7, 29.9 and 40.6%; atorvastatin in 40.9, 50.7 and 52.3%; and
simvastatin in 53.0, 30.0 and 24.6%. Use of metoprolol, ram-
ipril, valsartan, diltiazem and atorvastatin was more at ter-
tiary care while at primary care atenolol, lisinopril, losartan,
amlodipine and simvasatin use was more (c2 test for inter-
group difference, p < 0.01).T
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.4. Discussion
This study shows a substantial under-prescribing of cardio-
vascular evidence based medications in stable community
dwelling patients with CHD. There is low use of b-blockers,
ACE inhibitors and statins. The lowest use is at the primary
care level as reported earlier.13 Dual anti-platelet therapy is
widely used. Among b-blockers, ACE inhibitors, ARBs, CCBs
and statins, the most used molecules are atenolol, ramipril,
losartan, amlodipine and atorvastatin, respectively. Use of
second and third generationmolecules in these drug classes is
significantly greater at tertiary healthcare level compared to
secondary and primary healthcare levels.
Recent studies in Europe and North America have reported
a high use of evidence based drugs in patients with CHD for
secondary prevention.14 The serial EURO-ASPIRE studies in
Europe15 and large US based registries16 reported continuous
improvement in use of anti-platelets, b-blockers, ACE in-
hibitors or ARBs and statins. Only limited studies exist in low
income countries.17 There is also no systematic collection of
information of cardiovascular drug use in India and pre-
scription trends are usually available frommarketing research
conducted via pharmaceutical companies18 and not through
academic approach. The present study is an important land-
mark where we conducted the study to document the current
treatment trends for secondary prevention of CHD in Rajas-
than. Results of the present study have been compared with
the international studies performed since 2000’s (Table 3) and
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 2 5 0e2 5 5254show lower use of b-blockers, ACE inhibitors and statins as
compared to studies in high income countries.19 However, use
of various drugs classes is significantly greater than WHO-
PREMISE study17 performed in eight low and middle income
countries.
This study also shows significant differences in use of
different pharmacological molecules at primary, secondary
and tertiary levels of healthcare. While use of first genera-
tion molecules in various drug classes was the greatest at
primary care, second and third generation pharmaceutical
molecules were more frequently used at tertiary care level.
These findings are similar to studies from high income
countries.20 Use of first generation molecules such as aten-
olol, enalapril and lisinopril, losartan and simvastatin is high
among the primary care physicians while second and third
generation drugs are more used in secondary and tertiary
care.20
Physician behaviors are influenced by multiple factors.21
Studies in high income countries have reported large num-
ber of factors such as government guidelines, continuing
medical education, insurance coverage, peer-opinion, in-
dustry sponsored educational events, self-education and
experiential knowledge. Reasons for lowuse of evidence based
cardioprotective molecules have not been studied in India but
factors that influence the physician mind-lines (reported
above) could be important. Other factors could be poor
dissemination and uptake of results of study data from
Caucasian (non-Indian/Asian) populations, inequities in
health services, and resistance (by both doctor and patients) to
the cost and complexity of prescribingmultiple cardiovascular
medications. Barriers to adopting guideline recommendations
by doctorsmay include lack of understanding or translation to
clinical practice and patient profile.22 Although polypill
concept23 may improve compliance, greatest advance would
be to conduct studies in Indian subcontinentwhichwould lead
to more acceptable interpretation of the study results in the
indigenous population.24 Additionally, continued medical ed-
ucation directed on evidence based medicine rather than
experience based medicine may augment secondary preven-
tion and assist in reducing the anticipated growing burden of
CHD in India. The study has multiple limitations, reported
earlier,13 related to patient inclusion criteria (broad array of
CHD patients), sampling (healthcare facility based and not
population based), non-random physician selection and study
performed in a single state of India.
In conclusion, despite availability of evidence based
medicines at affordable prices there are significant gaps in
use of these secondary preventive medicines in India as
observed in the present study. We believe that the results can
be transposed to the whole country as Rajasthan is at the
median of national human development index.25 Larger
prospective national registries are required for future out-
comes research.Conflicts of interest
All authors have none to declare.r e f e r e n c e s
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